Tvardi Therapeutics, Inc.
TVRD
$3.98
$0.020.51%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.14M | 2.10M | 2.34M | 3.06M | 1.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.05M | 7.59M | 5.94M | 8.87M | 4.35M |
| Operating Income | -7.05M | -7.59M | -5.94M | -8.87M | -4.35M |
| Income Before Tax | -6.80M | -7.28M | -5.53M | 4.17M | -9.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.80M | -7.28M | -5.53M | 4.17M | -9.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.80M | -7.28M | -5.53M | 4.17M | -9.58M |
| EBIT | -7.05M | -7.59M | -5.94M | -8.87M | -4.35M |
| EBITDA | -7.03M | -7.56M | -5.91M | -8.85M | -4.33M |
| EPS Basic | -0.73 | -0.78 | -0.59 | 0.51 | -3.72 |
| Normalized Basic EPS | -0.45 | -0.48 | -0.37 | 0.32 | -2.32 |
| EPS Diluted | -0.73 | -0.78 | -0.59 | -1.00 | -3.72 |
| Normalized Diluted EPS | -0.45 | -0.48 | -0.37 | 0.31 | -2.32 |
| Average Basic Shares Outstanding | 9.38M | 9.38M | 9.38M | 8.25M | 2.58M |
| Average Diluted Shares Outstanding | 9.38M | 9.38M | 9.38M | 8.46M | 2.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |